cancer

Scientists identify a signature of cancers caused by mutant RAS that may lead to precise therapies.

For the 36th consecutive year, the UCSF School of Pharmacy has received more funding from the National Institutes of Health (NIH) than any other pharmacy school in the United States.

It can take just the flick of a genetic switch for breast cells to kick-start the normally well-regulated process of growth seen in puberty, pregnancy, or the menstrual cycle—or the mutation of that switch to initiate the unchecked proliferation of cancer.

A technology developed in the laboratory of James Wells, PhD, chair of the Department of Pharmaceutical Chemistry, UCSF School of Pharmacy, will drive a new approach to cancer treatment that switches on or triggers, with small molecules, the enzymes called caspases that promote cell death.

Research directed by senior author James Wells, PhD, chair of the Department of Pharmaceutical Chemistry, UCSF School of Pharmacy, has opened the door to a new way of studying and better understanding the processes of cell death (apoptosis), blood clotting, and other biochemical pathways.

Scientists from the UCSF School of Pharmacy's Department of Pharmaceutical Chemistry have been selected to lead a new federal initiative aimed at developing new classes of drugs to target cancer.